MAKO Surgical Posts a Solid Quarter: Here's What Investors Need to Know

It's OK, MAKO Surgical shareholders; you can exhale now.

Shares of the robotic surgery specialist traded up more than 4% after the company reported earnings yesterday. For those of you who are disappointed that the stock didn't absolutely skyrocket, remember that this muted response is a heck of a lot better than the violent 37% plunge investors endured after MAKO's dismal first quarter earnings last year.

MAKO RIO System, MAKO Surgical stock
MAKO RIO System, MAKO Surgical stock

Source: MAKO Surgical.

The numbers
On Monday, I noted that MAKO management desperately needed to at least meet tempered expectations to show investors they have a firm grasp on where the business is headed.

So, how did they fare?

On one hand, the company posted revenue of $24.8 million, slightly exceeding analysts' estimates, which called for sales of $24.4 million.

On the other hand, MAKO's net loss improved 18% year-over-year and came in at $9.6 million, or $0.21 per share. Unfortunately, that missed analysts' expectations of a net loss of $0.19 per share.

However, it's important to note that included in that number was "a non-cash and non-operating expense of $661,000 associated with the change in fair value of a derivative asset" related to the company's previously announced credit facility agreement with Deerfield Management. When we back out that expense, MAKO's non-GAAP loss was exactly what analysts had hoped for at $0.19 per share.

As an aside, management also told investors that they're confortable with MAKO's current cash balance, so have no intention of drawing on the costly Deerfield credit facility by the time it expires on May 15. As a result, they anticipate cash burn will increase as the inaction will invoke a $1 million "no draw fee" to Deerfield in the second quarter.

In addition, management also confirmed during the conference call that they agreed to pay approximately $1 million to Stanmore Implants to acquire the company's robotic assets as a result of last month's patent complaint resolution.

System sales
All told, five RIO systems were sold during the quarter -- this time all to domestic customers -- bringing MAKO's commercial installed base of RIO systems to 161 and with all but five here in the U.S. In addition, revenue from two previously deferred international sales was recognized this quarter after all revenue recognition criteria were satisfied.

Even better, all five of the new systems sold included MAKO's $150,000 total hip arthroplasty upgrade, while one existing customer upgraded its already-placed RIO platform with the THA add-on. As of March 31, 102 of the 156 RIO systems in place currently have the MAKOplasty THA application installed.

A total of 2,988 MAKOplasty procedures were performed last quarter, representing a 3% sequential increase and a 30% rise from the same year-ago period.

Of those 2,988 procedures, 467 were THA surgeries. While that may seem like only a small improvement over last quarter's 395 THA surgeries, remember that it represents an 18.2% sequential increase. Considering that MAKO's hip business is still in its infancy, 467 hip procedures is more than satisfactory.

Also, remember that the company told us last quarter it would be reporting monthly utilization numbers on a per-site rather than a per-system basis to better reflect the now-material contributions from non-commercial international systems. This quarter, monthly utilization per site fell to 6.6 procedures, compared with 7.1 procedures per site in the same year-ago period. Despite the drop, however, that number still remains well within the bounds of normality.

Guidance and cash burn
Keeping in mind that the first quarter of each year tends to be MAKO's slowest, the company felt comfortable maintaining its guidance of 45 to 48 RIO systems sold and 13,500 to 14,500 MAKOplasty procedures performed in 2013.

Finally, MAKO had cash and equivalents remaining of $71 million at the end of March, compared to $73.3 million as of Dec. 31, 2012. Management also reiterated they continue to expect to throw between $22 and $27 million in the oven when all is said and done at the end of this year, so should end 2013 with around $46 million in cash on the books.

Clinical research and marketing
MAKO also highlighted the previously announced favorable results of a randomized controlled trial involving 100 patients who underwent unicompartmental knee arthroplasty procedures. More specifically, 50 of the patients had opted for MAKO's robotic solution, and 50 had received manually placed Biomet Oxford implants.

According to yesterday's press release, the trial notes "MAKOplasty resulted in significantly lower post-operative pain from day one to eight weeks post-op and it took eight weeks for Oxford patients to reach the lower pain levels that MAKOplasty patients were already reporting after six days." What's more, MAKOplasty also proved more accurate "in all dimensions measured, with statistically significant differences in four of the six dimensions."

Of course, Biomet is a privately held company, but it's safe to say that trials like this should have other publicly traded companies like Stryker , Zimmer , and Johnson & Johnson sweating bullets given their competing manually placed implants. It also doesn't help their case that Johnson & Johnson in March lost its first of 10,750 lawsuits over defective metal-on-metal hip implants, but you can bet MAKO can't wait to capitalize on the fallout with its own innovative offerings.

Foolish final thoughts
In the end, MAKO shareholders are breathing a long-awaited sigh of relief after the company performed exactly as it said it would. Even so, with the stock trading more than 60% below its 52-week-high, you can bet we'll be watching closely to see whether MAKO can keep up the good work. If it can, the stock could very easily prove to be the multibagger that investors have been waiting for.

Zero to hero?
Sitting near all-time lows, has MAKO Surgical's robotic surgery growth story rusted over? To help investors answer this question, analyst and MAKO expert David Meier has authored a premium research report covering all of the must-know details on the company, including key areas to watch and risks looming in the future for the medical robotics company. Claim your copy by clicking here now.

The article MAKO Surgical Posts a Solid Quarter: Here's What Investors Need to Know originally appeared on

Fool contributor Steve Symington owns shares of MAKO Surgical . The Motley Fool recommends Johnson & Johnson and MAKO Surgical . The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.